BioDrugs

, Volume 27, Issue 3, pp 225–235 | Cite as

Belimumab Therapy in Systemic Lupus Erythematosus

Review Article

Abstract

Systemic lupus erythematosus (SLE) is a complex heterogeneous disease, posing challenges to clinical trials. As in other autoimmune diseases, B-lymphocytes play a central role in lupus pathogenesis. The finding that selection and survival of B cells are controlled by a variety of signals, including those provided by the longevity factor BAFF (B-cell activating factor), also called BLyS (B-lymphocyte stimulator), led to preclinical trials that revealed that BAFF represents a promising therapeutic target for human lupus. Belimumab is a fully human monoclonal antibody directed against BAFF. Lessons learned from early clinical trials led to improved methods and success of phase III trials, with recruitment of patients with both clinically and serologically active disease, development and use of a novel SLE Responder Index, and progressive and special restrictions on immunosuppressive and corticosteroid use. These studies offer an attractive blueprint to conduct future clinical trials in SLE. The overall steroid-sparing ability and benefits of belimumab on musculoskeletal and mucocutaneous organ systems suggest that it has an impact on the clinical management of SLE patients. Future directions include studies to determine the role of belimumab in early SLE, as well as in renal or CNS involvement.

References

  1. 1.
    Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med. 1999;189:1639–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol. 2001;2:764–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Zouali M. B lymphocytes—chief players and therapeutic targets in autoimmune diseases. Front Biosci. 2008;13:4852–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Hikada M, Zouali M. Multistoried roles for B lymphocytes in autoimmunity. Nat Immunol. 2010;11:1065–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Anolik JH, Barnard J, Cappione A, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54:3612–22.PubMedCrossRefGoogle Scholar
  8. 8.
    Merril J, Wallace D, Furie R, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE) Arthritis Rheum. 2010; 62: S608, 1457.Google Scholar
  9. 9.
    Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–76.PubMedCrossRefGoogle Scholar
  11. 11.
    Ansel KM, Cyster JG. Chemokines in lymphopoiesis and lymphoid organ development. Curr Opin Immunol. 2001;13:172–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–56.PubMedCrossRefGoogle Scholar
  13. 13.
    Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Khare SD, Sarosi I, Xia XZ, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA. 2000;97:3370–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807–17.PubMedGoogle Scholar
  16. 16.
    Do RK, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192:953–64.PubMedCrossRefGoogle Scholar
  17. 17.
    Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Hsu BL, Harless SM, Lindsley RC, et al. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol. 2002;168:5993–6.PubMedGoogle Scholar
  19. 19.
    Zouali M. B cell diversity and longevity in systemic autoimmunity. Mol Immunol. 2002;38:895–901.PubMedCrossRefGoogle Scholar
  20. 20.
    Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108–11.PubMedCrossRefGoogle Scholar
  21. 21.
    O’Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Scholz JL, Crowley JE, Tomayko MM, et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc Natl Acad Sci USA. 2008;105:15517–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang X, Park CS, Yoon SO, et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol. 2005;17:779–88.PubMedCrossRefGoogle Scholar
  24. 24.
    Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood. 2008;111:2755–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Batten M, Groom J, Cachero TG, Qian F, Schneider P, Tschopp J, Browning JL, Mackay F. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Meyer-Bahlburg A, Andrews SF, Yu KO, et al. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J Exp Med. 2008;205:155–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Ota M, Duong BH, Torkamani A, et al. Regulation of the B cell receptor repertoire and self-reactivity by BAFF. J Immunol. 2010;185:4128–36.PubMedCrossRefGoogle Scholar
  28. 28.
    Lesley R, Xu Y, Kalled SL, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity. 2004;20:441–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004;20:785–98.PubMedCrossRefGoogle Scholar
  30. 30.
    Zouali M, Sarmay G. B lymphocyte signaling pathways in systemic autoimmunity: implications for pathogenesis and treatment. Arthritis Rheum. 2004;50:2730–41.PubMedCrossRefGoogle Scholar
  31. 31.
    Ramanujam M, Wang X, Huang W, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest. 2006;116:724–34.PubMedCrossRefGoogle Scholar
  32. 32.
    Kahn P, Ramanujam M, Bethunaickan R, et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum. 2008;58:2824–34.PubMedCrossRefGoogle Scholar
  33. 33.
    Ramanujam M, Bethunaickan R, Huang W, et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum. 2010;62:1457–68.PubMedCrossRefGoogle Scholar
  34. 34.
    Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192:129–35.PubMedCrossRefGoogle Scholar
  35. 35.
    Cheema GS, Roschke V, Hilbert DM, et al. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis. 2003;62:168–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6–10.PubMedGoogle Scholar
  38. 38.
    Collins CE, Gavin AL, Migone TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8:R6.PubMedCrossRefGoogle Scholar
  39. 39.
    Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Halpern WG, Lappin P, Zanardi T, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006;91:586–99.PubMedCrossRefGoogle Scholar
  42. 42.
    Badr G, Borhis G, Lefevre EA, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood. 2008;111:2744–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.PubMedCrossRefGoogle Scholar
  44. 44.
    Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.PubMedCrossRefGoogle Scholar
  45. 45.
    Jacobi AM, Odendahl M, Reiter K, et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;48:1332–42.PubMedCrossRefGoogle Scholar
  46. 46.
    Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112:286–97.PubMedGoogle Scholar
  47. 47.
    Navarra S, Guzman R, Gallacher A, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.PubMedCrossRefGoogle Scholar
  48. 48.
    Furie R, Zamani O, Wallace D, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. Arthritis Rheum 2010; 62: S606, 1454.Google Scholar
  49. 49.
    Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143–51.PubMedCrossRefGoogle Scholar
  50. 50.
    Chatham W, Wallace D, Stohl W, et al. Effect of belimumab, a B-lymphocyte stimulator-specific inhibitor, on functional antibodies to pneumococcal, tetanus, and influenza vaccines. Arthritis Rheum 2010; 62: S192, 457.Google Scholar
  51. 51.
    Petri M, Levy R, Merril J, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 Studies. Arthritis Rheum 2010; 62: S190, 452.Google Scholar
  52. 52.
    van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328–37.PubMedCrossRefGoogle Scholar
  54. 54.
    Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, BLISS-52 and -76, and LBSL02 Study Groups, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum. 2005;52:1481–90.PubMedCrossRefGoogle Scholar
  56. 56.
    Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(10):3364–73.PubMedCrossRefGoogle Scholar
  57. 57.
    van Vollenhoven R, Gallacher A, Navarra S, et al. Belimumab, a BLys-specific inhibitor, reduced corticosteroid use in patients with active SLE: results from the phase 3 BLISS-52 and -76 Studies. Arthritis Rheum 2010; 62: S189, 451.Google Scholar
  58. 58.
    Zonana-Nacach A, Barr S, Magder LS, et al. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum. 2000;43:1801–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus. 2001;10:140–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82:299–308.CrossRefGoogle Scholar
  62. 62.
    Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Campbell R Jr, Cooper GS, Gilkeson GS. Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease. Arthritis Rheum. 2008;59:458–64.PubMedCrossRefGoogle Scholar
  64. 64.
    Robinson D Jr, Aguilar D, Schoenwetter M, et al. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res (Hoboken). 2010;62:266–73.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Inserm UMR-S 606ParisFrance
  2. 2.University Paris DiderotParisFrance
  3. 3.University of Santo Tomas HospitalManilaPhilippines
  4. 4.Metropolitan Medical CenterManilaPhilippines
  5. 5.Inserm U606, Centre Viggo Petersen, Hôpital LariboisièreParis Cedex 10France

Personalised recommendations